Takeda (TKPYY) CEO Christophe Weber said he is “very comfortable” with the rising competitive threat to Shire’s (SHPG) hemophilia business as he tries to secure investor support for his GBP46B takeover of the drugmaker, the Financial Times reports, citing an interview with Weber. The durability of the unit, which accounts for about 25% of Shire revenues, has raised questions among Takeda’s shareholders including how Shire plans to withstand pressure from a new competing drug made by Roche (RHHBY) and from experimental gene therapies being developed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.